BIONET Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	105.67	81.32	5.37	-
Revenue Growth (YoY)	143.89%	1414.60%	-	-
Cost of Revenue	85.44	79.3	3.57	-
Gross Profit	20.23	2.02	1.8	-
Selling, General & Admin	86.59	54.14	6.31	0.67
Research & Development	51.72	47.24	34.75	11.86
Operating Expenses	138.32	101.38	41.06	12.53
Operating Income	-118.09	-99.36	-39.26	-12.53
Interest & Investment Income	16.8	11.82	1.89	0.02
Other Non Operating Income (Expenses)	0.83	1.29	0.03	-
Pretax Income	-100.46	-86.26	-37.34	-12.52
Net Income	-100.46	-86.26	-37.34	-12.52
Net Income to Common	-100.46	-86.26	-37.34	-12.52
Shares Outstanding (Basic)	68	57	15	1
Shares Outstanding (Diluted)	68	57	15	1
Shares Change (YoY)	81.39%	280.50%	1278.45%	-
EPS (Basic)	-1.49	-1.50	-2.47	-11.43
EPS (Diluted)	-1.49	-1.50	-2.47	-11.43
Free Cash Flow	-180.3	-154.96	-46.26	-3.47
Free Cash Flow Per Share	-2.67	-2.70	-3.06	-3.17
Gross Margin	19.15%	2.48%	33.49%	-
Operating Margin	-111.75%	-122.19%	-731.20%	-
Profit Margin	-95.07%	-106.07%	-695.44%	-
Free Cash Flow Margin	-170.62%	-190.56%	-861.52%	-
EBITDA	-112.58	-96.12	-38.68	-
EBITDA Margin	-106.54%	-118.21%	-	-
D&A For EBITDA	5.51	3.24	0.58	-
EBIT	-118.09	-99.36	-39.26	-12.53
EBIT Margin	-111.75%	-122.19%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.